1. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet. 2021 Mar; 397(10272):387-397 (JIF: 60.392)
2. Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore. Tan IB, Tan C, Hsu LY, Dan YY, Aw A, Cook AR, Lee VJ. JAMA Netw Open. 2021 Feb; 325(6):584-585 (JIF: 56.27)
3. Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. Extermann M, Brain E, Canin B, Cherian MN, Cheung KL, de Glas N, Devi B, Hamaker M, Kanesvaran R, Karnakis T, Kenis C, Musolino N, O'Donovan A, Soto-Perez-de-Celis E, Steer C, Wildiers H; International Society of Geriatric Oncology. Lancet Oncol. 2021 Jan; 22(1):e29-e36 (JIF:33.752)
4. Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum. Dent R, Rugo HS. Lancet Oncol. 2021 Jan; 22(1):P27-28 (JIF: 33.752)
5. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Lancet Oncol. 2021 Apr; 22(4):499-511 (JIF: 33.752)
6. Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study. Yoo C, Kim JH, Ryu MH, Park SR, Lee JJX, Tai WMD, Chan SL, Ryoo BY. J Clin Oncol. 2021 Jan; 39(3_Suppl):272 (JIF: 32.956)
7. Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). Graham J, Wells C, Dudani S, Gan CL, Donskov F, Lee JL, Kollmannsberger CK, Pal SK, Beuselinck B, Hansen AR, North SA, Bjarnason GA, Agarwal N, Kanesvaran R, Wood L, Hotte SJ, McKay RR, Choueiri TK, Heng DYC. J Clin Oncol. 2021 Mar; 39(6_Suppl):316 (JIF: 32.956)
8. Investigation of a 22-gene genomic classifier (GC) for risk stratification and molecular subtyping in an Asian prostate cancer (PCa) cohort. J Clin Oncol. Yee WLS, Woo WY, Sim A, Low KP, Meng A, Tan JSH, Tuan J, Tan TWK, Wang MLC, Tay KJ, Cheng C, Yeong JPS, Lee LS, Kanesvaran R, Tan MCS, Davicioni E, Khor LY, Chua MLK. 2021 Mar; 39(6_Suppl):249 (JIF: 32.956)
9. Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Gan CL, Dudani S, Wells JC, Schmidt AL, Bakounu Z, Szabados B, Parnis F, Wong S, Lee JL, de Valasco G, Pal SK, Davis ID, Kanesvaran R, Wood L, Kollmannsberger CK, McKay RR, Neuselinck B, Donskov F, Choueiri TK, Heng DYC. J Clin Oncol. 2021 Mar; 39(6_Suppl):276 (JIF: 32.956)
10. Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Bancos I, Atkinson E, Eng C, Young William F, Neumann Hartmut PH, Yukina M, et al. Lancet Diabetes Endo. 2021 Jan; 9(1):P13-21 (JIF: 25.34)

* These are the top 10 publications in DMO for 2020.